Original Study| Volume 21, ISSUE 1, P194-202, February 2023

Download started.


Does the Time to Start First-Line Treatment Influence the Survival of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma? Results of the MetaSurv–UroCCR 79 Study


      Introduction and Objectives

      Many patients in the favorable International Metastatic renal cell carcinoma (RCC) Data Base Consortium group (F-MRC) may have a relatively indolent disease course. Surveillance and delay of systemic therapy could be an option in this specific population. However, the question whether this delay could alter patients’ outcome remains unanswered. Our objective was to determine if delaying first-line treatment influences the survival of F-MRC patients.

      Materials and Methods

      We performed a retrospective multicenter national study involving the French Network for Research on Kidney Cancer UroCCR (NCT03293563). We included treatment naive F-MRC patients. We compared the overall survival of patients with immediate medical treatment (IMT) (started less than 3 months after metastatic diagnosis) to those with delayed medical treatment (DMT).


      We included 90 patients treated between 2009 and 2018. The median time before occurrence of metastases from diagnosis was 28 (12-137) months. The two groups (IMT vs. DMT) were comparable for follow-up, age, sarcomatoid feature, number, and localization of metastatic sites and ECOG performance status. IMT was given in 25 (27.8 %) patients. Local treatment of metastasis (LTM) was performed in 47 (52%) patients. Patients with DMT had more LTM (63% vs. 24%, P = .001). Among patients with DMT (n = 65); 27 (41%) received a systemic treatment and median systemic treatment-free survival was 39 months (95% CI, 26.3-51.6). Median overall survival from metastasis disease diagnosis was 55 months (95% CI, 42.4-67.5) in the IMT group and 88 months (95%CI, 64-111.9) in the DMT group (P = .028). In multivariable analysis LTM was the only prognostic factor associated to survival improvement (HR: 0.33; P = .024).


      Selected Patients with F-MRC may safely undergo DMT. LTM positively impacted survival in this population and should be considered whenever possible. Prospective trial with a larger population is needed to confirm these results.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bray F
        • Ferlay J
        • Soerjomataram I
        • Siegel RL
        • Torre LA
        • Jemal A.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68 (nov): 394‑424
        • Heng DYC
        • Xie W
        • Regan MM
        • et al.
        Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
        J Clin Oncol. 2009; 27 (1 déc): 5794‑9
        • Motzer RJ
        • Tannir NM
        • McDermott DF
        • et al.
        Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.
        N Engl J Med. 2018; 378 (5 avr): 1277‑90
        • Choueiri TK
        • Powles T
        • Burotto M
        • et al.
        Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2021; 384 (4 mars): 829‑41
        • Grünwald V
        • Powles T
        • Choueiri TK
        • et al.
        Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
        Future Oncol. 2019; 15 (mars): 929‑41
        • Bedke J
        • Albiges L
        • Capitanio U
        • et al.
        Updated European association of urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma.
        Eur Urol. 2021; 79 (mars): 339‑42
        • Woldu SL
        • Matulay JT
        • Clinton TN
        • et al.
        Incidence and outcomes of delayed targeted therapy after cytoreductive nephrectomy for metastatic renal-cell carcinoma: a nationwide cancer registry study.
        Clin Genitourin Cancer. 2018; 16 (déc): e1221‑35
        • Harrison MR
        • Costello BA
        • Bhavsar NA
        • et al.
        Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
        Cancer. 2021; 127 (1 juill): 2204‑12
        • Rini BI
        • Dorff TB
        • Elson P
        • et al.
        Active surveillance in metastatic renal-cell carcinoma: a prospective, phase II trial.
        Lancet Oncol. 2016; 17 (sept): 1317‑24
        • Motzer RJ
        • Escudier B
        • McDermott DF
        • et al.
        Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase III clinical trial.
        J Immunother Cancer. 2020; 8 (e000891)
        • Ljungberg B
        • Bensalah K
        • Canfield S
        • et al.
        EAU guidelines on renal cell carcinoma: 2014 update.
        Eur Urol. 2015; 67 (mai): 913‑24
        • Matsubara N
        • Mukai H
        • Naito Y
        • Itoh K
        • Komai Y
        • Sakai Y.
        First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
        Urology. 2013; 82 (juill): 118‑23
        • Kushnir I
        • Basappa NS
        • Ghosh S
        • et al.
        Active surveillance in metastatic renal cell carcinoma: results from the canadian kidney cancer information system.
        Clin Genitourin Cancer. 2021; 19 (déc): 521‑30
        • Zaid HB
        • Parker WP
        • Safdar NS
        • et al.
        Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis.
        J Urol. 2017; 197 (janv): 44‑9
        • Omid S
        • Abufaraj M
        • Remzi M.
        Metastasectomy in patients with renal cell carcinoma: when and how?.
        Curr Opin Urol. 2020; 30 (juill): 602‑9
        • Bensalah K
        • Bigot P
        • Albiges L
        • et al.
        [French ccAFU guidelines - update 2020-2022: management of kidney cancer].
        Prog Urol. 2020; 30 (nov): S2‑51
        • Ralla B
        • Busch J
        • Flörcken A
        • et al.
        miR-9-5p in nephrectomy specimens is a potential predictor of primary resistance to first-line treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
        Cancers (Basel). 2018; 10: 321
        • Rini BI
        • Atkins MB.
        Resistance to targeted therapy in renal-cell carcinoma.
        Lancet Oncol. 2009; 10 (oct): 992‑1000
        • Rini BI
        • Plimack ER
        • Stus V
        • et al.
        Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2019; 380 (21 mars): 1116‑27
        • Motzer RJ
        • Penkov K
        • Haanen J
        • et al.
        Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2019; 380 (21 mars): 1103‑15
        • Beaumont JL
        • Salsman JM
        • Diaz J
        • et al.
        Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
        Cancer. 2016; 122 (1 avr): 1108‑15
        • Dudani S
        • de Velasco G
        • Wells JC
        • et al.
        Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival.
        JAMA Netw Open. 2021; 4 (4 janv)e2021869